0001493152-24-008891.txt : 20240305 0001493152-24-008891.hdr.sgml : 20240305 20240305172028 ACCESSION NUMBER: 0001493152-24-008891 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 EFFECTIVENESS DATE: 20240305 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biofrontera Inc. CENTRAL INDEX KEY: 0001858685 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473765675 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-506751 FILM NUMBER: 24722367 BUSINESS ADDRESS: STREET 1: 120 PRESIDENTIAL WAY, STREET 2: SUITE 330 CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 781-245-1325 MAIL ADDRESS: STREET 1: 120 PRESIDENTIAL WAY, STREET 2: SUITE 330 CITY: WOBURN STATE: MA ZIP: 01801 D 1 primary_doc.xml X0708 D LIVE 0001858685 Biofrontera Inc. 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA MASSACHUSETTS 01801 781-245-1325 DELAWARE None None Corporation true Hermann Luebbert c/o Biofrontera Inc. 120 Presidential Way, Suite 330 Woburn MA MASSACHUSETTS 01801 Executive Officer Director Eugene Frederick Leffler, III c/o Biofrontera Inc 120 Presidential Way, Suite 330 Woburn MA MASSACHUSETTS 01801 Executive Officer John J. Borer III c/o Biofrontera Inc. 120 Presidential Way, Suite 330 Woburn MA MASSACHUSETTS 01801 Director Beth J. Hoffman c/o Biofrontera Inc. 120 Presidential Way, Suite 330 Woburn MA MASSACHUSETTS 01801 Director Heikki Lanckriet c/o Biofrontera Inc. 120 Presidential Way, Suite 330 Woburn MA MASSACHUSETTS 01801 Director Kevin D. Weber c/o Biofrontera Inc. 120 Presidential Way, Suite 330 Woburn MA MASSACHUSETTS 01801 Director Pharmaceuticals Decline to Disclose 06b false 2024-02-19 false true true true false 0 Roth Capital Partners, LLC 15407 None None 888 SAN CLEMENTE, SUITE 400 NEWPORT BEACH CA CALIFORNIA 92660 MD MARYLAND NV NEVADA NY NEW YORK true 8000000 8000000 0 The Company sold approximately 6,586 shares of Series B-1 Convertible Preferred Stock and warrants to purchase shares of Series B-3 Convertible Preferred Stock as first disclosed on its Current Report on Form 8-K filed with the SEC on February 20, 2024. false 8 685000 0 0 false Biofrontera Inc. /s/ E. Fred Leffler, III E. Fred Leffler, III Chief Financial Officer 2024-03-05